Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.
- Published In:
- Journal of hypertension, 35(4), 761-768 (2017)
- Authors:
- White, William B, Myers, Martin G, Jordan, Robert(2), Lucas, Johna
- Database ID:
- RPEP-03520
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03520APA
White, William B; Myers, Martin G; Jordan, Robert; Lucas, Johna. (2017). Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.. Journal of hypertension, 35(4), 761-768. https://doi.org/10.1097/HJH.0000000000001221
MLA
White, William B, et al. "Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.." Journal of hypertension, 2017. https://doi.org/10.1097/HJH.0000000000001221
RethinkPeptides
RethinkPeptides Research Database. "Usefulness of ambulatory blood pressure monitoring to assess..." RPEP-03520. Retrieved from https://rethinkpeptides.com/research/white-2017-usefulness-of-ambulatory-blood
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.